Myriad Genetics (MYGN) Return on Equity (2016 - 2025)
Myriad Genetics (MYGN) has disclosed Return on Equity for 15 consecutive years, with 0.99% as the latest value for Q4 2025.
- On a quarterly basis, Return on Equity fell 81.0% to 0.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.99%, a 81.0% decrease, with the full-year FY2025 number at 0.68%, down 51.0% from a year prior.
- Return on Equity was 0.99% for Q4 2025 at Myriad Genetics, up from 1.05% in the prior quarter.
- In the past five years, Return on Equity ranged from a high of 0.01% in Q1 2022 to a low of 1.05% in Q3 2025.
- A 5-year average of 0.29% and a median of 0.17% in 2023 define the central range for Return on Equity.
- Peak YoY movement for Return on Equity: surged 39bps in 2021, then plummeted -90bps in 2025.
- Myriad Genetics' Return on Equity stood at 0.03% in 2021, then crashed by -342bps to 0.12% in 2022, then tumbled by -189bps to 0.36% in 2023, then surged by 50bps to 0.18% in 2024, then tumbled by -455bps to 0.99% in 2025.
- Per Business Quant, the three most recent readings for MYGN's Return on Equity are 0.99% (Q4 2025), 1.05% (Q3 2025), and 0.72% (Q2 2025).